1 ventricular arrhythmias (11% versus 1%), and
die from a cardiac cause (2% versus 0%) than family memb
2 s alpha-syn to accumulate; such cells likely
die from a combination of ER stress and excessive accumu
3 succumbed to COVID-19 and four patients who
died from a COVID-19-unrelated cause.
4 was isolated from the brain of a patient who
died from a rapidly progressing demyelinating disease kn
5 om one patient in the chemotherapy group who
died from a secondary tumour (head and neck anaplastic e
6 virus was first isolated from a patient who
died from a severe respiratory illness in June, 2012, in
7 s three (2%) patients in the docetaxel group
died from a treatment-related adverse event.
8 Four children
died from a treatment-related toxic effect; one (<1%) of
9 t, and for the last 8 y the number of plants
dying from a sudden wilt disease has increased, leading
10 1499 (66.7%) of 2246 individuals
died from accidental causes and 604 (26.9%) died by suic
11 reasons for hospital admission of those who
died from acute myocardial infarction.
12 gs obtained during autopsy from patients who
died from acute respiratory distress syndrome (ARDS) sec
13 th ADV viremia died by D +180; 8 of 15 (53%)
died from ADV.
14 Nine patients
died from adverse events; five of these deaths were judg
15 Four (2%) patients
died from adverse events; one (pulmonary embolism in tre
16 d become newly infected, and 1.6 million had
died from AIDS-related causes.
17 We estimate that, of people
dying from AIDS between 2010 and 2030, most will have in
18 g for sociodemographic factors, patients who
died from alcohol-related liver disease had the highest
19 edents were included, of whom 56 065 (41.2%)
died from alcohol-related liver disease.
20 artery disease did not increase the risk to
die from all or vascular causes.
21 ng the 76 186 person-years of follow-up, 748
died from all causes.
22 6,587 participants died from CVD, and 21,376
died from all causes.
23 he lives of many more mammals than have ever
died from allergy, so justifying the positive role of Ig
24 nd bronchopulmonary LNs of 11 nonsmokers who
died from an asthma exacerbation (fatal asthma [FA]) in
25 One patient
died from an intracranial haemorrhage that was judged by
26 sociated with greater risk of developing and
dying from an SPC, compared with the general population.
27 rgan donor, the PHS donor was younger, male,
died from anoxia, more likely to be HCV and antibody rea
28 on control parents who had not had offspring
die from any sudden cause during the study period.
29 NP versus 78 patients (27%) who increased it
died from any cause (adjusted hazard ratio=0.53; 95% con
30 m, 261 (0.7%) died by suicide and 832 (2.2%)
died from any cause within 12 months.
31 ants reached the primary end point and 49.1%
died from any cause.
32 gher for 18 of the 30 FPC types, and risk of
dying from any SPCs was statistically significantly high
33 gher for 21 of the 31 FPC types, and risk of
dying from any SPCs was statistically significantly high
34 a-VEGF (D/R) or (D/-) groups, animals mainly
died from arterial thromboembolisms and in the alpha-VEG
35 tin treatment, experienced ASCVD events, and
died from ASCVD-related or non-ASCVD-related causes base
36 In addition, C/EBPgamma-deficient newborns
die from atelectasis and respiratory failure, which can
37 HDAC3-deficient mice
died from autoimmunity by 4-6 weeks of age; however, inj
38 -antibiotic era", one where more people will
die from bacterial infections than from cancer.
39 erienced SBCE, 627 had a recurrence, and 237
died from breast cancer.
40 Ninety patients (12.8%)
died from breast cancer.
41 rapy and four of 40 assigned to radiotherapy
died from breast cancer.
42 is the major risk factor for developing and
dying from breast cancer.
43 rticipants experienced a BSI, and 451 (0.8%)
died from BSI.
44 ATM-null mice exhibit A-T disease but they
die from cancer before the neurological symptoms are man
45 en 2020 and 2050, 11.1 million children will
die from cancer if no additional investments are made to
46 eople with mental illness are more likely to
die from cancer, we assessed whether people with mental
47 ent, data were gathered for 308 patients who
died from cancer (147 in LCP-I programme wards and 161 i
48 Most patients
died from cancer (n = 20).
49 ive cardiovascular events and a major number
dies from cancer.
50 r (HR 1.16, 95% CI 1.08-1.24, p < 0.001) and
dying from cancer (HR 1.27, 95% CI 1.15-1.41, p < 0.001)
51 ients with cancer according to their risk of
dying from cancer relative to overall mortality.
52 y being linked to the risk of developing and
dying from cancer.
53 ted: one patient in the FGFR2(non-mut) group
died from cardiac arrest with contributing reason of pul
54 One (2%) patient
died from cardiac arrest, possibly treatment related.
55 red in four (3%) patients: one (<1%) patient
died from cardiac death, one (<1%) patient had periproce
56 to week 24, one patient in the placebo group
died from cardiac failure and two had serious infections
57 ) of 31 patients with successful implant had
died from cardiac reasons, with no cardiac deaths occurr
58 Women are more likely to suffer and
die from cardiogenic shock (CS) as the most severe compl
59 death in the rivaroxaban group; this patient
died from cardiogenic shock on day 50 after a type A aor
60 A higher proportion of patients with NAFLD
die from cardiovascular disorders than patients with ALD
61 atients (49.3%) in the medical-therapy group
died from cardiovascular causes (hazard ratio, 0.79; 95%
62 , 558 (13.3%) and 693 (16.5%), respectively,
died from cardiovascular causes (hazard ratio, 0.80; 95%
63 Fewer patients
died from cardiovascular causes in the liraglutide group
64 son-years of follow-up, 77 patients died; 35
died from cardiovascular causes, of which 15 were sudden
65 p, 81 (12%) patients died, of which 38 (47%)
died from cardiovascular causes.
66 One control
died from cardiovascular collapse.
67 The unadjusted proportion of patients who
died from cardiovascular disease increased as eGFR decre
68 total of 4,952 men died, of which 1,637 men
died from cardiovascular diseases (CVD), 2,122 from canc
69 loping acute myocardial infarction (AMI) and
dying from cardiovascular causes in comparison to three
70 lity of 30% for these patients, the majority
dying from cardiovascular causes.
71 of patients with stage 2 disease and an SVR
died from causes secondary to HCC (2.0%) compared with t
72 n sub-Saharan Africa continue to acquire and
die from cerebral malaria, despite efforts to control or
73 One patient in the caplacizumab group
died from cerebral ischemia after the end of the treatme
74 Blantyre, Malawi, on pediatric patients who
died from cerebral malaria and controls.
75 reased brain volume was seen in children who
died from cerebral malaria but was uncommon in those who
76 rocyte sequestration in patients with or who
died from cerebral malaria.
77 Two patients
died from chronic GVHD or unrecognized drug rash with eo
78 pair group and 8.2% in the open-repair group
died from chronic obstructive lung disease; between-grou
79 ive, nationwide analysis of all patients who
died from cirrhosis in England between 2013 and 2015, wh
80 a mean follow-up of 14.7 years, 114 subjects
died from cirrhosis; 33 of them from viral hepatitis B (
81 In 18 Malawian children who
died from clinically defined CM, we studied the intensit
82 eated with buprenorphine and morphine do not
die from clostridial myonecrosis.
83 cells in brain sections from 34 children who
died from CM or other causes.
84 Thirteen children had MR and
died from CM.
85 One person
died from colon carcinoma unrelated to study medication.
86 versus 996 individuals in the control group
died from colorectal cancer.
87 w that such late arrivers are more likely to
die from competition with great tits.
88 and drought-tolerant species, and trees that
died from competition.
89 patients were lost to follow-up, 4 patients
died from complications of cardiac surgery, and 2 patien
90 One patient
died from complications of elective reconstructive surge
91 One patient
died from complications of IMN and one died from complic
92 tient died from complications of IMN and one
died from complications of the haematological disease.
93 5 y of follow-up, 329 men died from CVD, 148
died from coronary heart disease (CHD), and 72 men died
94 mply, for example, that if 190,000 Americans
die from COVID-19, as some models project, then ~1.7 mil
95 anges in the peripheral lung of patients who
die from Covid-19.
96 gs obtained during autopsy from patients who
died from Covid-19 and compared them with 7 lungs obtain
97 Patients who
died from COVID-19 often had comorbidities, such as hype
98 Among the 326 patients who
died from Covid-19, 70.6% were black.
99 In patients who
died from Covid-19-associated or influenza-associated re
100 Black/African Americans are contracting and
dying from COVID-19 disproportionately.
101 n of minority individuals diagnosed with and
dying from COVID-19.
102 One participant in the T3 group
died from cranial trauma after a motor vehicle accident.
103 In the UC cohort, 639 patients
died from CRC (0.55 per 1000 person-years), compared wit
104 s advanced CRC, and are at increased risk of
dying from CRC, although these excess risks have decline
105 g-positive patient, who defaulted from care,
died from cryptococcal meningitis (CM).
106 ual numbers of people who are developing and
dying from cryptococcal meningitis.
107 During 25 y of follow-up, 329 men
died from CVD, 148 died from coronary heart disease (CHD
108 riod of 16.7 (3.2) years, 6,587 participants
died from CVD, and 21,376 died from all causes.
109 During the follow-up, 556 participants
died from CVD.
110 1 killer of women; only 11% knew a woman who
died from CVD.
111 D (HR 1.39, 95% CI 1.34-1.43, p < 0.001) and
dying from CVD (HR 1.45, 95% CI 1.29-1.62, p < 0.001), a
112 limiting toxicity, including one patient who
died from diffuse alveolar damage following a dose of 50
113 HIV-infected CD4(+) T cells
die from direct virus-induced apoptosis and CD8 T-cell-m
114 A single sham-vaccinated macaque
died from disease due to EBOV infection.
115 Three patients
died from disease progression within 30 days after infus
116 had had rapid neurologic deterioration, had
died from disease progression.
117 ent of the three who relapsed in this cohort
died from disease.
118 ridley turtles (Lepidochelys olivacea) that
died from drowning bycatch in fisheries and 44 live or f
119 reatment; one patient in the gefitinib group
died from drug-related hepatic and renal failure.
120 No patients
died from drug-related toxic effects.
121 tients who underwent RFA of BE, less than 1%
died from EAC.
122 Five patients
died from early progression (n = 2), sepsis (1) or after
123 A 9-month-old infant
died from Ebola virus (EBOV) disease with unknown epidem
124 The results showed that elephants
dying from EEHV1 hemorrhagic disease or ill from EEHV in
125 of the patients required transplantation or
died from end-stage liver disease.
126 Four patients (22%)
died from endocarditis or complications to treatment, 2
127 Out of 171 patients identified, 2 had
died from esophageal carcinoma.
128 o present three case reports of patients who
died from EVALI to illustrate the clinical characteristi
129 the country on their 15th birthday, and who
died from external causes (cases) were matched by age an
130 We identified 2246 individuals who
died from external causes, whom we matched to 44 920 liv
131 se disorder are at particularly high risk of
dying from external causes.
132 Globally, trees are increasingly
dying from extreme drought, a trend that is expected to
133 Two patients
died from from myocardial infarction potentially related
134 One patient was initially thought to have
died from grade 5 radiation pneumonitis during the study
135 of patients with stage 1 disease and an SVR
died from HCC (2.9%), compared with those without an SVR
136 atients expressed worry about developing and
dying from HCC, but nearly half (49.9%) of patients repo
137 d the brain vasculature from 34 children who
died from HCM or other causes and frequently found CD3+
138 ull sample died during follow-up, and 22 152
died from heart disease.
139 Three patients
died from heart failure within the first week of life.
140 ath certificates, approximately 1800 persons
die from hepatitis B annually in the United States; howe
141 died (3 with disease progression, 1 of whom
died from Hodgkin's lymphoma); there had been 20 instanc
142 90(ko/ko) mice exhibit early vision loss and
die from hydrocephalus.
143 approximately 257,800 people are expected to
die from IE by 2030.
144 related to cancer (7.2%); one patient (0.6%)
died from incidentally detected medullary thyroid cancer
145 e find that mated females are more likely to
die from infection, suffer higher pathogen burdens, and
146 as similar (7 days), but more NB-PC patients
died from infection (26% versus 8%, P < 0.01).
147 Although 2 patients
died from infection, 3 recovered and experienced brief r
148 one vaccinated animal and the control animal
died from infection.
149 , and in the 10-day group six patients (14%)
died from infection.
150 f treatment; one patient receiving sorafenib
died from infectious colitis while on treatment and four
151 One patient
died from influenza B encephalitis during an endemic out
152 decades of life, more individuals in the USA
die from injuries and violence than from any other cause
153 One patient
died from intracranial bleeding after relapse.
154 onors were significantly more likely to have
died from intracranial hemorrhage than were all other de
155 c lung cancer, one patient assigned riluzole
died from ischaemic heart disease and coronary artery th
156 have been saved for each exposed worker who
died from ischemic heart disease.
157 osed with the disease, and about 49,000 will
die from it.
158 tuberculosis in 2013 and 1.5 million people
died from it.
159 Four of the 6 recipients who developed KS
died from KS or associated complications.
160 eas a higher proportion of patients with ALD
die from liver disease.
161 highest chance of hospital death; people who
died from liver cancer were less likely to die in hospit
162 , and Dec 31, 2015, 13 818 people in England
died from liver disease and had large-volume paracentesi
163 ssociated with hospital death for people who
died from liver disease.
164 (66.9% [95% CI 66.6-67.1]) for patients who
died from liver disease.
165 were from liver failure (2 of the women who
died from liver failure had received isoniazid [1 in eac
166 BV or HCV infection, only 6 developed HCC or
died from liver-related disease.
167 the 1690 HBV carriers developed HCC and 126
died from liver-related diseases.
168 Despite early tumor resection, mice
died from locally recurring and distant tumors, but adju
169 range of cognitive ability increase risk of
dying from lower respiratory tract infection.
170 to identify those most likely to develop or
die from lung cancer.
171 icipants in the T0 negative group would have
died from lung cancer (a rise in mortality from 185.82 [
172 at an early stage and can reduce the risk of
dying from lung cancer.
173 ated cells may be due in part to these cells
dying from lytic EBV infection when they differentiate a
174 x vivo PrPSc derived from the brains of mice
dying from M1000 prion disease.
175 00 to 53% in 2012, many children continue to
die from malaria.
176 Each year, over 16,000 patients
die from malignant brain cancer in the US.
177 ve treatment; one patient assigned amiloride
died from metastatic lung cancer, one patient assigned r
178 00 platelets/microL and albuminemia <35 g/L)
died from multiorgan failure.
179 d broad-spectrum antibiotics, she ultimately
died from multiorgan failure.
180 we find that 70% of Mef(-/-)Rad50(s/s) mice
die from multiple myeloma or other plasma cell neoplasms
181 l graft-versus-host disease, and the patient
died from multiple organ failure 4 months after transpla
182 oung children fail to thrive and adolescents
die from myocardial infarction or stroke.
183 y related to treatment; another patient also
died from myocardial infarction related to sepsis.
184 old, a 26-fold, and a 18-fold higher risk of
dying from myocardial infarction, heart failure, or stro
185 We have recently demonstrated that RPE cells
die from necrosis in response to oxidative stress, provi
186 of brigatinib, including eight patients who
died from neoplasm progression.
187 Whereas normoxia-treated KO mice
die from neurodegeneration at about 60 d, hypoxia-treate
188 However, only one patient
died from NLPHL.
189 17 (5%) of 370 patients
died from non-treatment-related adverse events associate
190 n increase in the proportion of HIV patients
dying from non-AIDS-related disorders.
191 Four patients
died from nonarrhythmic causes.
192 r survivors of breast cancer will ultimately
die from nonbreast cancer-related causes.
193 .5 months, 92 patients were alive, whereas 4
died from noncardiac causes.
194 nt's age, whereas the proportion of patients
dying from noncardiac causes, such as cancer, increased.
195 ents had a fatal outcome; of those, 88 (78%)
died from nonsurvivable TBI or brain death.
196 Within the study time, 36 patients
died from NSCLC and 26 patients from other causes.
197 ion after circulatory death (DCD) donors who
died from opioid overdose is unknown.
198 illion) and 109 500 people (105 800-113 600)
died from opioid overdose.
199 -45.6%; P = .017), and 8.2% of aspirin users
died from other causes (95% CI, 4.6%-13.2%) vs 26.7% of
200 ts, 7,365 died of prostate cancer and 11,811
died from other causes during a median follow-up of 2.8
201 essive disorder and control subjects who had
died from other causes.
202 women with eclampsia died, and a further 51
died from other complications of hypertensive disorders
203 The hazard ratios for
dying from other causes were biased, which introduced bi
204 pret this estimate in the context of risk of
dying from other causes, and aid in decision-making.
205 n the lifestyle and medical management group
died (from pancreatic cancer), thus 119 were included in
206 Whereas no patients
died from PBC, the 5-year survival rate was 75%, as comp
207 not seem to significantly affect the risk of
dying from PCa.
208 erness areas supplies bears that likely will
die from people, but these bears are essential to avert
209 Of these 15 patients, 3
died from persistent infection postoperatively, whereas
210 Lung tissue of patients who had
died from pneumococcal pneumonia or a nonpulmonary cause
211 vismodegib therapy, except for 1 patient who
died from possibly treatment-related sepsis (grade 5 adv
212 /or reversible causes - many children likely
die from potentially reversible kidney disease because t
213 y for signs and symptoms of ischemia, 1 in 5
died from predominantly cardiac pathogeneses within 9 ye
214 VS161, CDC42), implying that mid2Delta cells
die from premature fusion without a partner.
215 sk prostate cancer between 1998 and 2011 who
died from prostate cancer (cases) and 1,710 matched cont
216 ely 30% of patients with soft-tissue sarcoma
die from pulmonary metastases.
217 mong participants who received tofersen, one
died from pulmonary embolus on day 137, and one from res
218 One patient
died from pulmonary sepsis leading to multi-organ failur
219 Two patients eventually
died from radioembolization-induced liver disease.
220 Patients
die from recurrent tumors that have become resistant to
221 d 49 (2%) of 2093 patients in the APBI group
died from recurring breast cancer.
222 One patient with congestive heart failure
died from refractory left ventricular failure.
223 Several members of a family
died from renal failure as a result of systemic amyloido
224 ay 152; one participant in the placebo group
died from respiratory failure on day 52.
225 e is evidence that they have a lower risk of
dying from respiratory disease as a whole.
226 irst-degree relatives of individuals who had
died from SADS.
227 Each year about 400,000 patients
die from sepsis, hospital acquired infections, venous th
228 past, and these patients are more likely to
die from sepsis.
229 all patients given golimumab in the study, 3
died (from sepsis, tuberculosis, and cardiac failure, al
230 Three infants
died from sepsis after random assignment.
231 t 6 months of follow-up except 1 patient who
died from sepsis at 1 month.
232 One patient (4%)
died from sepsis in the context of neutropenic fever, in
233 laparotomy for a perforated peptic ulcer and
died from sepsis.
234 enness were associated with reduced risks of
dying from several common causes of death among urban Ca
235 -KO) develop systemic autoimmune disease and
die from severe anemia between 18 and 80 days of age.
236 All donors
died from severe head trauma.
237 cholecystectomy for gallbladder empyema and
died from severe respiratory failure.
238 The patient
died from sinusoidal obstruction syndrome-associated mul
239 The risk of an Indian
dying from snakebite before age 70 is about 1 in 250, bu
240 that could have been saved among persons who
died from specific cardiovascular causes by enforcing th
241 rom coronary heart disease (CHD), and 72 men
died from stroke.
242 e developing liver, and Gata4-mutant embryos
died from subsequent liver hypoplasia and anemia.
243 wo (2%) patients, both in the placebo group,
died from sudden cardiac death during follow-up.
244 Each year, almost 1 million people
die from suicide, which is among the leading causes of d
245 ed of 2 or more children in which at least 1
died from suicide.
246 RNA alterations in hearts from patients who
died from systemic sepsis, in comparison to changed mess
247 cytokine concentrations were more likely to
die from TBM.
248 tments prolong survival, many patients still
die from the disease and survivors suffer severe long-te
249 alaria but was uncommon in those who did not
die from the disease, a finding that suggests that raise
250 women will develop melanoma and 10,100 will
die from the disease.
251 nts with invasive pneumococcal disease (IPD)
die from the disease.
252 ed States, and nearly 11,000 are expected to
die from the disease.
253 ht serve to identify patients more likely to
die from the SARS-CoV-2 infection, regardless of age.
254 ospital admission with cirrhosis (n=1518) or
died from the disease (n=42).
255 nd prostate cancer (3,811 cases, 511 of whom
died from the disease, compared with 2,980 controls-from
256 eveloped tuberculosis and 1.5 million people
died from the disease.
257 Of these, 98 had
died from the disease.
258 Carp maintained at 24 degrees C
died from the infection, whereas those housed in multi-c
259 Fifty percent of cases
died from the infection.
260 ival of many people who would otherwise have
died from the initial loss of blood.
261 It remains unclear whether the Plesioteuthis
died from the pterosaur attack or survived for some time
262 tive impairment persisted and she eventually
died from the sequelae of her disease.
263 Every devil that is 'infected' with DFTD
dies from the cancer.
264 substantially reduced the number of children
dying from the disease in India.
265 tor targets are achieved, the probability of
dying from the four main NCDs between the ages of 30 yea
266 r concordant causes of death (i.e., siblings
dying from the same causes) but not for discordant cause
267 o increased survival, many MB patients still
die from their disease, and patients who survive suffer
268 lf of the patients, while the other patients
die from their disease.
269 t, patients with prostate cancer continue to
die from their disease.
270 ical injury, thereby allowing the patient to
die from their original disorder.
271 more heart disease, and were more likely to
die from their primary liver cancer (all P < 0.0001).
272 vors of Ebola virus disease who subsequently
died from their closest family members.
273 ced disease progression, whereas 13 patients
died from their disease.
274 ssive disease, and one patient (2%) each had
died from therapy-related or other causes.
275 ostate cancer, and more than 26,000 men will
die from this disease in 2016.
276 n's risk estimate in separating patients who
died from those who survived at 30 days (c-index, 0.78 v
277 ha]/CCL3), which segregated participants who
died from those who survived.
278 logeneic stem-cell transplantation and later
died from transplantation-related complications.
279 Three patients in the ramucirumab group
died from treatment-emergent adverse events that were ju
280 ed nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
died from treatment-related adverse events (myasthenia g
281 vents associated with death, and one patient
died from treatment-related adverse events (myositis in
282 No patients
died from treatment-related adverse events and four pati
283 g group; four (1%) versus two (<1%) patients
died from treatment-related adverse events.
284 11 patients
died from treatment-related causes (three in the twice-d
285 Five (2%) patients
died from treatment-related causes in the combination gr
286 ed nivolumab 3 mg/kg plus ipilimumab 1 mg/kg
died from treatment-related pneumonitis.
287 One patient assigned to pembrolizumab
died from treatment-related sepsis.
288 illions of individuals are infected with and
die from tuberculosis (TB) each year, and multidrug-resi
289 In 2017, 1.6 million people worldwide
died from tuberculosis (TB).
290 000-298 000) children younger than 15 years
died from tuberculosis worldwide in 2015; 80% (191 000,
291 quently, most patients with advanced disease
die from tumor progression.
292 More than 90% of cancer patients
died from tumor metastasis, instead of primary tumor gro
293 Patients
died from tumor progression (55%), cholangitis (18%), pn
294 At the end of follow-up, two patients
died from tumor progression, the other 10 patients were
295 mo) after (90)Y TARE, and 41 patients (53%)
died from tumor progression.
296 1 tumors and favorable MYC staining patterns
died from tumor-related causes.
297 Of 10 ambulatory patients, 5
died from untreated VF, 4 had cardiac arrests requiring
298 We estimate that 7803 Rohingya
died from violent and non-violent causes associated with
299 Whether cells
dying from viral infection exhibit a cell death-type mod
300 Each year, 3.4 million people
die from waterborne diseases worldwide.